Pharmaceuticals
Cure8 research brief
Why This Matters
Researchers tested manumycin A in a standard mouse colitis model and observed reduced inflammation and tissue injury, suggesting the compound might be a candidate for further IBD drug development.
Who Should Pay Attention
Researchers, preclinical pharmacologists, and clinicians interested in IBD drug discovery and immune-pathway research
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preclinical paper reports that manumycin A, a natural polyketide, reduced inflammation and tissue damage in a mouse model of colitis (3% DSS) when given by intraperitoneal injection.
The study measured disease activity index, colon length, histology, and local expression of pro-inflammatory cytokines (IL‑1β, IL‑6, TNF‑α, IFN‑γ) and found dose-dependent protective effects. The work is an early, laboratory-stage (animal) study testing therapeutic potential; it does not provide human safety or efficacy data.
The compound was compared with 5‑ASA as a positive control in mice, and some endpoints (body weight) were not significantly different between groups.
If you read the paper, note that outcomes are from a controlled mouse experiment (DSS colitis) with intraperitoneal dosing; translation to human treatment, dosing, safety, or clinical benefit requires extensive further research.
Keep In Mind
Findings come from a DSS-induced colitis mouse model with intraperitoneal dosing; animal results often do not predict human outcomes. This report does not include human clinical data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPharmaceuticals
PublisherMDPI AG
AuthorsChun-Sik Bae, Jin-Woo Park, Soon-Young Lee +4 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: National Research Foundation of Korea, award RS-2022-NR070862; award RS-2022-NR070862; Ministry of Education, award 2026-RISE-14-001; award 2026-RISE-14-001
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis.
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor.
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...